

Alpenglow Biosciences Introduces LUMI: A Breakthrough Imaging Interface
Discover LUMI, the intuitive imaging interface for Alpenglow’s 3D i™ HOTLS microscope. Unveiled at ABRF 2025, LUMI streamlines 3D imaging workflows with real-time previews and seamless operation.

Alpenglow Biosciences Secures $24M+ in ARPA-H and NIH Contracts to Revolutionize Cancer and Prostate Diagnostics
Alpenglow Biosciences has secured over $24M in contracts from ARPA-H and NIH to revolutionize cancer and prostate diagnostics. These groundbreaking collaborations include a five-year ARPA-H contract for precision tumor removal and an NIH SBIR Phase II contract for advanced prostate cancer diagnostics.

Alpenglow Biosciences and Mayo Clinic enter a collaboration agreement to advance pathology and drug development.
Alpenglow Biosciences has partnered with Mayo Clinic to integrate its cutting-edge 3D spatial biology platform, combining high-throughput 3D imaging, automated data processing, and AI-powered analysis. This collaboration aims to accelerate drug development and enhance clinical diagnostics, particularly in cancer treatment response.

Alpenglow Biosciences and CorePlus partner together to bring 3D Spatial Biology to clinical research and development
Alpenglow Biosciences has partnered with CorePlus to bring 3D spatial biology to clinical research and drug development. Through this collaboration, CorePlus will use Alpenglow's 3Deep Imager to digitize tissues and gain novel spatial insights, accelerating the development of new therapies.